46 drug, including 14 locally manufactured meds, samples fail quality tests in Himachal
- Himachal BJP’s Bihari Lal slams CM’s media adviser Naresh Chauhan for lying on poll promises - November 17, 2024
- Bird flu alert sounded in Himachal as migratory winged visitors arrive; wildlife officials start collecting samples - November 17, 2024
- Indora Govt Girls Senior Secondary School students take out anti-drug rally under ‘Nasha-Mukt Bharat’ campaign - November 16, 2024
The Newz Radar
Shimla: In January, samples of 46 drugs, including 14 manufactured in Himachal Pradesh, have failed quality tests conducted by the Central Drugs Standard Control Organization (CDSCO).
Among the 14 drugs from Himachal Pradesh, three are from Sirmaur, one from Kangra, and 10 from Solan district.
These drugs were found to be non-compliant with standards for treating skin infections, bacterial infections, appetite stimulation, allergies, irregular uterine bleeding, anemia, acidity, allergies, diabetes, and pain.
In January, a total of 932 drug samples were collected nationwide, out of which 886 passed and 46 failed the quality tests.
The drugs that failed the quality tests include:
Clindamycin for skin infections from Sanwet Healthcare in Paonta Sahib.
Emikacin Sulfate for bacterial infections from Equinox Pharmaceuticals in Baddi.
Cyproheptadine Triacolate for appetite stimulation from Pankha Lab in Paonta Sahib.
Moxifloxacin for allergies from Pankha Lab in Paonta Sahib.
Tranexamic Acid and Mefenamic Acid for irregular uterine bleeding from J Lab in Paonta Sahib.
Folic Acid for anemia from Enj Pharma in Malqu Majra.
Pantoprazole for acidity from Halero Labs in Brotiwala.
Levocetirizine for allergies from Hiller Lab in Barotiwala.
Glimepiride and Metformin Pioglitazone for diabetes from Megnatec Pharma in Barotiwala.
Montelukast Levocetirizine for allergies from Rachil Pharma in Kangra district.
Diclofenac for pain from Enj Life Sciences in Malqu Majra.
The industries whose drug samples failed the tests will be issued notices stating the reasons and will be required to recall the stocks from the market. The department will also conduct its own investigation into these samples.
